EBV (GP350/GP340) Peptide Pool
€301.30*
Description
Peptide pool of 224 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Envelope glycoprotein GP350/GP340 (UniProt ID: P03200) of Epstein-Barr virus (EBV, Humanes Herpesvirus 4, HHV4).
One unit allows the stimulation of 2,5 x 108 cells.
gp350/gp340 versus gp350/220
The EBV envelope glycoprotein gp350/gp340 (or gp350/220) is encoded by the BLLF1 gene and represents one of the most abundant surface proteins of the virion. The protein exists in multiple isoforms generated by alternative splicing. While gp350 denotes the full-length form, gp340 and gp220 refer to truncated isoforms of the same glycoprotein, which retain identical biological function. Differences in naming (gp340 vs. gp220) arise from historical nomenclature, experimental detection methods, and variations in glycosylation state.
Initial attachment and endocytosis
Gp350/gp340 belongs to the core set of EBV glycoproteins that define viral tropism and host cell interaction – together with gp42, BMRF2, gH/gL, and gB. Gp350/gp340 plays a central role in viral attachment and entry into B lymphocytes. Through molecular mimicry of complement components, gp350/gp340 specifically recognizes complement receptor 1 (CR1/CD35) and complement receptor 2 (CR2/CD21) on B cells. This interaction mediates the initial attachment of EBV particles and triggers endocytosis of the immobilized virion, marking the first step of EBV infection in B lymphocytes.
Major target of immune responses
Due to its surface exposure, high abundance, and essential role in viral entry, gp350/gp340 represents a major target of humoral and cellular immune responses. Peptides derived from gp350/gp340 are widely used to study EBV-specific T cell immunity, epitope recognition, and immune monitoring in the context of EBV infection, EBV-associated malignancies, and vaccine development.
The EBV (gp350/gp340) Peptide Pool from peptides&elephants provides comprehensive sequence coverage of this key viral glycoprotein and is ideally suited for applications such as T cell stimulation assays, epitope mapping, and immunological profiling in EBV research.
TechData
| Gene: | BLLF1 |
| Delivery: | 1-3 days |
| Counterion: | TFA |
| Length: | 907 amino acids |
| No. Peptides: | 224 peptides |
| Amount/Aliquote: | 15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 108 cells |
| Solubility: | Dissolve in a minimum amount of pure DMSO (40µl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system. |
| Protein: | Envelope glycoprotein GP350 |
| UniProt Id: | P03200 |
| Species: | Epstein-Barr virus (EBV; Human herpesvirus 4) |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Infectious disease, Cancer, Neuroscience |
More EBV Peptide Pools
